Zentralklinikum Bad Berka

Hospital


Location: Bad Berka, Germany (DE) DE


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Immunoprofiling in Neuroendocrine Neoplasms: Implications for Immunotherapy (2019) Busse A, Spenke C, Arsenic R, Briest F, Sipos B, Kaemmerer D, Pavel ME, et al. Conference contribution COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET (2018) Pavel ME, Rinke A, Baum RP Conference contribution Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR (2018) Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, et al. Journal article Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018) Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al. Conference contribution Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial (2018) Pavel ME, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, et al. Journal article Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study (2018) Dillon JS, Kulke MH, Pavel ME, Horsch D, Anthony LB, Warner RRP, Bergsland E, et al. Conference contribution Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial (2018) Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, et al. Conference contribution FATTY LESIONS DETECTED ON MRI SCANS IN PATIENTS WITH ANKYLOSING SPONDYLITIS ARE BASED ON THE DEPOSITION OF FAT IN THE VERTEBRAL BONE MARROW (2018) Baraliakos X, Boehm H, Barakat AS, Schett G, Braun J Conference contribution
1 2 3 4 5